Crescent Biopharma (CBIO) Return on Capital Employed (2014 - 2026)
Crescent Biopharma (CBIO) posted quarterly Return on Capital Employed of 97.72% for Q2 2026, up 30.0% year-over-year from 75.17% in Q2 2025, and down 23.1% quarter-over-quarter from 79.38% in Q1 2026.
Crescent Biopharma (CBIO) Return on Capital Employed (2014 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Return on Capital Employed for 13 consecutive years, with 97.72% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 30.0% year-over-year to 97.72%; the TTM figure through Jun 2026 stood at 97.72% (up 30.0% YoY), while the FY2025 annual figure was 149.81%, down 2004.0% from the prior year.
- Return on Capital Employed retreated to 97.72% in Q2 2026 per CBIO's latest filing, from 79.38% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 61.41% in Q3 2025 and bottomed at 311.01% in Q4 2024.
- Historically, Return on Capital Employed has averaged 127.55% across 5 years, with a median of 97.87% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 21843 bps — and 2026, when it surged 21206 bps.
- Crescent Biopharma's Return on Capital Employed stood at 105.33% in 2022, then rose by 12 bps to 92.58% in 2023, then sank by 236 bps to 311.01% in 2024, then jumped by 68 bps to 99.62% in 2025, then gained by 2 bps to 97.72% in 2026.
- Business Quant data shows CBIO's Return on Capital Employed at 97.72% in Q2 2026, 79.38% in Q1 2026, and 99.62% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | -97.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -97.72% |
| Mar 31, 2026 | -79.38% |
| Dec 31, 2025 | -99.62% |
| Sep 30, 2025 | -61.41% |
| Jun 30, 2025 | -98.02% |
| Mar 31, 2025 | -291.44% |
| Dec 31, 2024 | -311.01% |
| Sep 30, 2024 | -268.78% |
| Jun 30, 2024 | -163.80% |
| Mar 31, 2024 | -114.46% |
| Dec 31, 2023 | -92.58% |
| Sep 30, 2023 | -78.85% |
| Jun 30, 2023 | -66.77% |
| Mar 31, 2023 | -81.46% |
| Dec 31, 2022 | -105.33% |
| Sep 30, 2022 | -102.75% |
| Jun 30, 2022 | -97.60% |
| Mar 31, 2022 | -84.96% |
| Dec 31, 2021 | -71.03% |
| Sep 30, 2021 | -57.83% |